Pub Date : 2023-12-09DOI: 10.1007/s12094-023-03353-9
An An Li, Yu Zhang, Fan Li, Yang Zhou, Zhi li Liu, Xin Hua Long
{"title":"Correction to: The mechanism of VCP‑mediated metastasis of osteosarcoma based on cell autophagy and the EMT pathway","authors":"An An Li, Yu Zhang, Fan Li, Yang Zhou, Zhi li Liu, Xin Hua Long","doi":"10.1007/s12094-023-03353-9","DOIUrl":"https://doi.org/10.1007/s12094-023-03353-9","url":null,"abstract":"","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138561370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Progression after first-line immunochemotherapy (ICT) for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) is a clinical concern due to subsequent limited treatment options. This study firstly predicted the progress outcome.
Methods
A cohort of 186 R/M NPC cases that received first-line ICT was included for developing a Cox regression model for progression-free survival (PFS) and risk stratification, which was verified by cross-validation. Discrimination and calibration were evaluated. Progression sites in risk groups was shown with a Sankey diagram.
Results
Baseline predictors including liver metastasis, trend of plasma Epstein–Barr virus DNA copies, lymphocyte-to-monocyte ratio, and level of platelet and lactate dehydrogenase were identified for model construction, which stratify the cohort into low, middle, and high-risk groups. The overall concordance index (C-index) was 0.67 (95% CI 0.62–0.73). The area under the curve (AUC) was 0.68 (95% CI 0.60–0.76), 0.74 (95% CI 0.66–0.82), 0.75 (95% CI 0.65–0.84) at predicting 12, 18, and 24 months PFS, indicating a moderate accuracy. Cross-validation showed the model performance was robust. Compared with the low-risk group (median PFS: 24.4 months, 95% CI 18.4 months to not reached), the high-risk group (median PFS: 7.1 months, 95% CI 6.4–10.1 months; hazard risk: 7.4, 95% CI 4.4–12.4, p < 0.001) progressed with more liver metastasis after ICT resistance.
Conclusion
It was the first study that described the risk factors and progression characteristics in R/M NPC patients who received first-line ICT, investigating the progression patterns, which was helpful to identify patients with different risks and help guide personalized interventions.
目的复发性或转移性鼻咽癌(R/M NPC)一线免疫化疗(ICT)后的进展是临床关注的问题,因为后续治疗方案有限。本研究首先对进展结果进行了预测。方法纳入了186例接受一线ICT治疗的R/M鼻咽癌病例,建立了无进展生存期(PFS)和风险分层的Cox回归模型,并通过交叉验证进行了验证。对判别和校准进行了评估。结果 在构建模型时,确定了包括肝转移、血浆 Epstein-Barr 病毒 DNA 拷贝数趋势、淋巴细胞与单核细胞比率、血小板和乳酸脱氢酶水平在内的基线预测因素,并将队列分为低、中、高风险组。总体一致性指数(C-index)为 0.67(95% CI 0.62-0.73)。在预测 12、18 和 24 个月的 PFS 时,曲线下面积(AUC)分别为 0.68(95% CI 0.60-0.76)、0.74(95% CI 0.66-0.82)、0.75(95% CI 0.65-0.84),表明准确度适中。交叉验证结果表明,该模型性能稳健。与低风险组(中位 PFS:24.4 个月,95% CI 18.4 个月至未达到)相比,高风险组(中位 PFS:7.1 个月,95% CI 6.4-10.1 个月;危险风险:7.4,95% CI 4.4-12.4,p <0.001)在 ICT 耐药后出现更多肝转移。结论这是第一项描述接受一线ICT治疗的R/M鼻咽癌患者风险因素和进展特征的研究,调查了其进展模式,有助于识别不同风险的患者,帮助指导个性化干预。
{"title":"Predictive progression outcomes and risk stratification in patients with recurrent or metastatic nasopharyngeal carcinoma who received first-line immunochemotherapy","authors":"Danjie He, Yudong Zhang, Shuiqing He, Yuzhuo Zhang, Keyao Dai, Cheng Xu, Ying Huang","doi":"10.1007/s12094-023-03344-w","DOIUrl":"https://doi.org/10.1007/s12094-023-03344-w","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Progression after first-line immunochemotherapy (ICT) for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) is a clinical concern due to subsequent limited treatment options. This study firstly predicted the progress outcome.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A cohort of 186 R/M NPC cases that received first-line ICT was included for developing a Cox regression model for progression-free survival (PFS) and risk stratification, which was verified by cross-validation. Discrimination and calibration were evaluated. Progression sites in risk groups was shown with a Sankey diagram.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Baseline predictors including liver metastasis, trend of plasma Epstein–Barr virus DNA copies, lymphocyte-to-monocyte ratio, and level of platelet and lactate dehydrogenase were identified for model construction, which stratify the cohort into low, middle, and high-risk groups. The overall concordance index (C-index) was 0.67 (95% CI 0.62–0.73). The area under the curve (AUC) was 0.68 (95% CI 0.60–0.76), 0.74 (95% CI 0.66–0.82), 0.75 (95% CI 0.65–0.84) at predicting 12, 18, and 24 months PFS, indicating a moderate accuracy. Cross-validation showed the model performance was robust. Compared with the low-risk group (median PFS: 24.4 months, 95% CI 18.4 months to not reached), the high-risk group (median PFS: 7.1 months, 95% CI 6.4–10.1 months; hazard risk: 7.4, 95% CI 4.4–12.4, p < 0.001) progressed with more liver metastasis after ICT resistance.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>It was the first study that described the risk factors and progression characteristics in R/M NPC patients who received first-line ICT, investigating the progression patterns, which was helpful to identify patients with different risks and help guide personalized interventions.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138561408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-09DOI: 10.1007/s12094-023-03356-6
Carlos Ayala-de Miguel, Jerónimo Jiménez-Castro, Adrián Sánchez-Vegas, Sebastián Díaz-López, Manuel Chaves-Conde
Appendiceal mucinous lesions’ classification and nomenclature has been modified several times along the last decades, reflecting their great heterogeneity and making difficult to compare results and draw conclusions. Despite its nearby origin, appendiceal mucinous lesions have a distinctive behaviour compared to colorectal cancer, including their molecular and genetic markers. Due to their low frequency, their management is not well standardised. However, surgery is considered the cornerstone of treatment. Their indolent behaviour has encouraged surgeons to apply more aggressive treatments, such as cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC), that may extend overall survival. Chemotherapy is reserved for unresectable and/or disseminated disease and could play a role in the adjuvant and neoadjuvant setting. Pressurised intraperitoneal aerosol chemotherapy (PIPAC) is recently emerging as a possible alternative for treatment in advanced disease although its results in long-term survival are lacking Hereby, we review the available evidence in the management of appendiceal mucinous lesions, including localised and disseminated disease, with a special emphasis on the oncological perspective, focusing on the lights and shadows of the systemic treatments.
{"title":"Neoplastic appendiceal mucinous lesions: a narrative review of the literature from an oncologist’s perspective","authors":"Carlos Ayala-de Miguel, Jerónimo Jiménez-Castro, Adrián Sánchez-Vegas, Sebastián Díaz-López, Manuel Chaves-Conde","doi":"10.1007/s12094-023-03356-6","DOIUrl":"https://doi.org/10.1007/s12094-023-03356-6","url":null,"abstract":"<p>Appendiceal mucinous lesions’ classification and nomenclature has been modified several times along the last decades, reflecting their great heterogeneity and making difficult to compare results and draw conclusions. Despite its nearby origin, appendiceal mucinous lesions have a distinctive behaviour compared to colorectal cancer, including their molecular and genetic markers. Due to their low frequency, their management is not well standardised. However, surgery is considered the cornerstone of treatment. Their indolent behaviour has encouraged surgeons to apply more aggressive treatments, such as cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC), that may extend overall survival. Chemotherapy is reserved for unresectable and/or disseminated disease and could play a role in the adjuvant and neoadjuvant setting. Pressurised intraperitoneal aerosol chemotherapy (PIPAC) is recently emerging as a possible alternative for treatment in advanced disease although its results in long-term survival are lacking Hereby, we review the available evidence in the management of appendiceal mucinous lesions, including localised and disseminated disease, with a special emphasis on the oncological perspective, focusing on the lights and shadows of the systemic treatments.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"310 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138561200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-09DOI: 10.1007/s12094-023-03347-7
Laia Bernet-Vegué, Carolina Cantero-González, Magdalena Sancho de Salas, David Parada, Tiziana Perin, Zulma Quintero-Niño, Begoña Vieites Pérez-Quintela, Douglas Sánchez-Guzmán, Marina Castelvetere, David Hardisson Hernaez, María Dolores Martín-Salvago
Purpose
This study aimed to validate the classification of breast cancer (BC) patients in progression risk groups based on total tumor load (TTL) value to predict lymph node (LN) affectation after neo-adjuvant systemic therapy (NAST) obtained in the NEOVATTL study.
Methods/patients
This was an observational, retrospective, international, multicenter study including patients with infiltrating BC who received NAST followed by sentinel lymph node biopsy (SLNB) analyzed with one-step nucleic acid amplification (OSNA) from nine Spanish and two Italian hospitals. Patients were classified into three groups according to the progression risk, measured as disease-free survival (DFS), based on TTL values (> 250, 250–25,000, and > 25,000 copies/μL). The previous (NEOVATTL study) Cox regression model for prognosis was validated using prognostic index (PI) and Log ratio test (LRT) analyses; the value of TTL for axillary non-SLN affectation was assessed using receiver operating characteristic (ROC) curves.
Results
We included 263 patients with a mean age of 51.4 (± SD 10.5) years. Patients with TTL > 25,000 copies/μL had a shorter DFS (HR 3.561 [95% CI 1.693−7.489], p = 0.0008 vs. TTL ≤ 25,000). PI and LRT analyses showed no differences between the two cohorts (p = 0.2553 and p = 0.226, respectively). ROC analysis showed concordance between TTL and non-SLN involvement (area under the curve 0.828), with 95.7% sensitivity and 92.9% specificity at a TTL cut-off of > 15,000 copies/μL.
Conclusions
In BC patients who had received NAST and underwent SLNB analysis using OSNA, a TTL value of > 25,000 copies/μL was associated with a higher progression risk and > 15,000 copies/μL was predictive of non-SLN involvement.
目的本研究旨在验证基于总肿瘤负荷(TTL)值的乳腺癌(BC)患者进展风险组别分类,以预测 NEOVATTL 研究中获得的新辅助全身治疗(NAST)后淋巴结(LN)受影响的情况。方法/患者这是一项观察性、回顾性、国际多中心研究,包括来自西班牙九家医院和意大利两家医院的浸润性BC患者,他们在接受NAST治疗后进行了前哨淋巴结活检(SLNB),并进行了一步核酸扩增(OSNA)分析。根据 TTL 值(250、250-25,000 和 25,000 拷贝/μL),以无疾病生存期(DFS)为衡量标准,将患者按疾病进展风险分为三组。使用预后指数(PI)和对数比值检验(LRT)分析验证了先前的(NEOVATTL 研究)Cox 回归预后模型;使用接收器操作特征曲线(ROC)评估了 TTL 对腋窝非淋巴结影响的价值。TTL>25,000拷贝/μL的患者DFS较短(HR 3.561 [95% CI 1.693-7.489], p = 0.0008 vs. TTL ≤ 25,000)。PI 和 LRT 分析表明,两个组群之间没有差异(分别为 p = 0.2553 和 p = 0.226)。ROC分析显示,TTL与非SLN受累之间存在一致性(曲线下面积为0.828),在TTL临界值为> 15,000拷贝/μL时,灵敏度为95.7%,特异度为92.9%。结论在接受过NAST并使用OSNA进行SLNB分析的BC患者中,TTL值为> 25,000拷贝/μL与较高的进展风险相关,而> 15,000拷贝/μL可预测非SLN受累。
{"title":"Validation of prognostic and predictive value of total tumoral load after primary systemic therapy in breast cancer using OSNA assay","authors":"Laia Bernet-Vegué, Carolina Cantero-González, Magdalena Sancho de Salas, David Parada, Tiziana Perin, Zulma Quintero-Niño, Begoña Vieites Pérez-Quintela, Douglas Sánchez-Guzmán, Marina Castelvetere, David Hardisson Hernaez, María Dolores Martín-Salvago","doi":"10.1007/s12094-023-03347-7","DOIUrl":"https://doi.org/10.1007/s12094-023-03347-7","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>This study aimed to validate the classification of breast cancer (BC) patients in progression risk groups based on total tumor load (TTL) value to predict lymph node (LN) affectation after neo-adjuvant systemic therapy (NAST) obtained in the NEOVATTL study.</p><h3 data-test=\"abstract-sub-heading\">Methods/patients</h3><p>This was an observational, retrospective, international, multicenter study including patients with infiltrating BC who received NAST followed by sentinel lymph node biopsy (SLNB) analyzed with one-step nucleic acid amplification (OSNA) from nine Spanish and two Italian hospitals. Patients were classified into three groups according to the progression risk, measured as disease-free survival (DFS), based on TTL values (> 250, 250–25,000, and > 25,000 copies/μL). The previous (NEOVATTL study) Cox regression model for prognosis was validated using prognostic index (PI) and Log ratio test (LRT) analyses; the value of TTL for axillary non-SLN affectation was assessed using receiver operating characteristic (ROC) curves.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>We included 263 patients with a mean age of 51.4 (± SD 10.5) years. Patients with TTL > 25,000 copies/μL had a shorter DFS (HR 3.561 [95% CI 1.693−7.489], <i>p</i> = 0.0008 vs. TTL ≤ 25,000). PI and LRT analyses showed no differences between the two cohorts (<i>p</i> = 0.2553 and <i>p</i> = 0.226, respectively). ROC analysis showed concordance between TTL and non-SLN involvement (area under the curve 0.828), with 95.7% sensitivity and 92.9% specificity at a TTL cut-off of > 15,000 copies/μL.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>In BC patients who had received NAST and underwent SLNB analysis using OSNA, a TTL value of > 25,000 copies/μL was associated with a higher progression risk and > 15,000 copies/μL was predictive of non-SLN involvement.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"45 1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138561167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-08DOI: 10.1007/s12094-023-03352-w
Benjamin Robles-Bañuelos, Adriana Romo-Perez, Guadalupe Dominguez-Gomez, Alma Chavez-Blanco, Aurora Gonzalez-Fierro, Alfonso Duenas-Gonzalez
Drug repurposing of widely prescribed patent-off and cheap drugs may provide affordable drugs for cancer treatment. Nevertheless, many preclinical studies of cancer drug repurposing candidates use in vitro drug concentrations too high to have clinical relevance. Hence, preclinical studies must use clinically achievable drug concentrations. In this work, several FDA-approved cancer drugs are analyzed regarding the correlation between the drug inhibitory concentrations 50% (IC50) tested in cancer cell lines and their corresponding peak serum concentration (Cmax) and area under the curve (AUC) reported in clinical studies of these drugs. We found that for most targeted cancer drugs, the AUC and not the Cmax is closest to the IC50; therefore, we suggest that the initial testing of candidate drugs for repurposing could select the AUC pharmacokinetic parameter and not the Cmax as the translated drug concentration for in vitro testing. Nevertheless, this is a suggestion only as experimental evidence does not exist to prove this concept. Studies on this issue are required to advance in cancer drug repurposing.
{"title":"Selection of clinically relevant drug concentrations for in vitro studies of candidates drugs for cancer repurposing: a proposal","authors":"Benjamin Robles-Bañuelos, Adriana Romo-Perez, Guadalupe Dominguez-Gomez, Alma Chavez-Blanco, Aurora Gonzalez-Fierro, Alfonso Duenas-Gonzalez","doi":"10.1007/s12094-023-03352-w","DOIUrl":"https://doi.org/10.1007/s12094-023-03352-w","url":null,"abstract":"<p>Drug repurposing of widely prescribed patent-off and cheap drugs may provide affordable drugs for cancer treatment. Nevertheless, many preclinical studies of cancer drug repurposing candidates use in vitro drug concentrations too high to have clinical relevance. Hence, preclinical studies must use clinically achievable drug concentrations. In this work, several FDA-approved cancer drugs are analyzed regarding the correlation between the drug inhibitory concentrations 50% (IC<sub>50</sub>) tested in cancer cell lines and their corresponding peak serum concentration (<i>C</i><sub>max)</sub> and area under the curve (AUC) reported in clinical studies of these drugs. We found that for most targeted cancer drugs, the AUC and not the <i>C</i><sub>max</sub> is closest to the IC<sub>50</sub>; therefore, we suggest that the initial testing of candidate drugs for repurposing could select the AUC pharmacokinetic parameter and not the <i>C</i><sub>max</sub> as the translated drug concentration for in vitro testing. Nevertheless, this is a suggestion only as experimental evidence does not exist to prove this concept. Studies on this issue are required to advance in cancer drug repurposing.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"64 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138556590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}